CAMBRIDGE, Mass., Dec. 31, 2012 /PRNewswire/ -- Metamark Genetics, Inc., a privately held, oncology-focused molecular diagnostics company, announced today that its scientific co-founder Lynda Chin, MD, has resigned from the Metamark board of directors. Dr. Chin is a leader in cancer genomics, member of the Institute of Medicine of the National Academy of Science, Scientific Director of the Institute for Applied Cancer Science, and founding Chair of the department of Genomic Medicine at MD Anderson Cancer Center. She has pioneered the use of comparative oncogenomics to discover new drug targets and diagnostics for cancer patients and is one of this nation's leading entrepreneurs. Commenting on the transition, company co-founder Kenneth E. Weg stated, "Lynda has been a visionary, leading the way to predict the prognosis of early stage cancers so that we can identify the patients who are most at risk for disease progression. We are thankful for her insight and guidance on our board." Dr. Chin stated, "I am excited by Metamark's progress, particularly its recent achievement of critical clinical and commercial milestones. This strong scientific and financial foundation will enable Metamark to impact on the enormous problem of prostate cancer management and more. I am extremely grateful to Metamark for realizing my dream of translating scientific discoveries into meaningful clinical advances for patients."
About Metamark Genetics, Inc.
Metamark is a privately held oncology company focused on the development of molecular function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.
SOURCE Metamark Genetics, Inc.